The Scottish Medicines Consortium has approved a new first-line combination therapy for restricted use in adults with unresectable or metastatic urothelial cancer.
UK-based study identifies key patient-centered factors influencing treatment preferences in high-risk NMIBC ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results